Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Linezolid | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Linezolid. |
| Furazolidone | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Furazolidone. |
| Procaine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Procaine. |
| Tranylcypromine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Tranylcypromine. |
| Phenelzine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenelzine. |
| Minaprine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Minaprine. |
| Selegiline | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Selegiline. |
| Procarbazine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Procarbazine. |
| Moclobemide | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Moclobemide. |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Isocarboxazid. |
| Rasagiline | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Rasagiline. |
| Pargyline | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Pargyline. |
| Clorgiline | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Clorgiline. |
| Iproniazid | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Iproniazid. |
| Nialamide | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Nialamide. |
| Safinamide | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Safinamide. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | The risk or severity of adverse effects can be increased when Methylecgonine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. |
| Methylene blue | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Methylene blue. |
| Hydracarbazine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Hydracarbazine. |
| Pirlindole | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Pirlindole. |
| Toloxatone | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Toloxatone. |
| Benmoxin | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Benmoxin. |
| Mebanazine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Mebanazine. |
| Octamoxin | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Octamoxin. |
| Pheniprazine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Pheniprazine. |
| Phenoxypropazine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenoxypropazine. |
| Pivhydrazine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Pivhydrazine. |
| Safrazine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Safrazine. |
| Caroxazone | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Caroxazone. |
| Harmaline | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Harmaline. |
| Brofaromine | The risk or severity of adverse effects can be increased when Methylecgonine is combined with Brofaromine. |
| Metoclopramide | The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methylecgonine. |
| Spironolactone | The risk or severity of orthostatic hypotension can be increased when Methylecgonine is combined with Spironolactone. |